Title | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | McFaline-Figueroa, JL, Braun, CJ, Stanciu, M, Nagel, ZD, Mazzucato, P, Sangaraju, D, Cerniauskas, E, Barford, K, Vargas, A, Chen, Y, Tretyakova, N, Lees, JA, Hemann, MT, White, FM, Samson, LD |
Journal | Cancer Res |
Volume | 75 |
Issue | 15 |
Pagination | 3127-38 |
Date Published | 2015 Aug 1 |
ISSN | 1538-7445 |
Keywords | Animals, Antineoplastic Agents, Alkylating, Carmustine, Cell Line, Tumor, Dacarbazine, DNA Modification Methylases, DNA Repair Enzymes, DNA-Binding Proteins, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Gene Knockdown Techniques, Genes, p53, Glioblastoma, Humans, Mice, Inbred C57BL, MutS Homolog 2 Protein, Radiation, Ionizing, Survival Analysis, Tumor Suppressor Proteins, Xenograft Model Antitumor Assays |
Abstract | Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment. Here, we report that in GBM cells, even a modest decrease in the mismatch repair (MMR) components MSH2 and MSH6 have profound effects on temozolomide sensitivity. RNAi-mediated attenuation of MSH2 and MSH6 showed that such modest decreases provided an unexpectedly strong mechanism of temozolomide resistance. In a mouse xenograft model of human GBM, small changes in MSH2 were sufficient to suppress temozolomide-induced tumor regression. Using The Cancer Genome Atlas to analyze mRNA expression patterns in tumors from temozolomide-treated GBM patients, we found that MSH2 transcripts in primary GBM could predict patient responses to initial temozolomide therapy. In recurrent disease, the absence of microsatellite instability (the standard marker for MMR deficiency) suggests a lack of involvement of MMR in the resistant phenotype of recurrent disease. However, more recent studies reveal that decreased MMR protein levels occur often in recurrent GBM. In accordance with our findings, these reported decreases may constitute a mechanism by which GBM evades temozolomide sensitivity while maintaining microsatellite stability. Overall, our results highlight the powerful effects of MSH2 attenuation as a potent mediator of temozolomide resistance and argue that MMR activity offers a predictive marker for initial therapeutic response to temozolomide treatment. |
DOI | 10.1158/0008-5472.CAN-14-3616 |
Alternate Journal | Cancer Res. |
PubMed ID | 26025730 |
PubMed Central ID | PMC4526337 |
Grant List | 5F31CA165735 / CA / NCI NIH HHS / United States DP1 ES022576 / ES / NIEHS NIH HHS / United States DP1-ES022576 / DP / NCCDPHP CDC HHS / United States F31 CA165735 / CA / NCI NIH HHS / United States P30 CA014051 / CA / NCI NIH HHS / United States P30 ES002109 / ES / NIEHS NIH HHS / United States P30-CA014051 / CA / NCI NIH HHS / United States P30-ES002109 / ES / NIEHS NIH HHS / United States R01 CA184320 / CA / NCI NIH HHS / United States R01 ES022872 / ES / NIEHS NIH HHS / United States R01-ES022872 / ES / NIEHS NIH HHS / United States T32 GM007287 / GM / NIGMS NIH HHS / United States T32 GM081081 / GM / NIGMS NIH HHS / United States T32-GM081081 / GM / NIGMS NIH HHS / United States T32GM007287 / GM / NIGMS NIH HHS / United States U54 CA112967 / CA / NCI NIH HHS / United States U54-CA112967 / CA / NCI NIH HHS / United States |